|Other Names||Eukaryotic translation initiation factor 2A, eIF-2A, 65 kDa eukaryotic translation initiation factor 2A, Eukaryotic translation initiation factor 2A, N-terminally processed, EIF2A|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13720b was selected from the C-term region of EIF2A. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Functions in the early steps of protein synthesis of a small number of specific mRNAs. Acts by directing the binding of methionyl-tRNAi to 40S ribosomal subunits. In contrast to the eIF- 2 complex, it binds methionyl-tRNAi to 40S subunits in a codon- dependent manner, whereas the eIF-2 complex binds methionyl-tRNAi to 40S subunits in a GTP-dependent manner.|
|Tissue Location||Widely expressed. Expressed at higher level in pancreas, heart, brain and placenta|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
EIF2A is a 65-kD protein that catalyzes the formation ofpuromycin-sensitive 80S preinitiation complexes (Zoll et al., 2002[PubMed 12133843]).
Groskreutz, D.J., et al. J. Biol. Chem. 285(31):24023-24031(2010)Bailey, S.D., et al. Diabetes Care (2010) In press :Willis, K.L., et al. Virology 394(1):73-81(2009)Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009)Spurgeon, M.E., et al. J. Virol. 83(19):9970-9982(2009)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.